Close



Dec 11, 2023 03:46AM
Dec 10, 2023 07:30PM
Dec 6, 2023 08:16AM
Dec 6, 2023 08:15AM
Nov 30, 2023 05:00PM
Nov 30, 2023 05:00PM
Nov 3, 2023 12:00PM Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunothe
Nov 2, 2023 01:01PM
Nov 2, 2023 01:00PM
Nov 1, 2023 08:00AM
Oct 22, 2023 10:30AM
Oct 22, 2023 10:30AM
Oct 12, 2023 08:00AM
Sep 22, 2023 05:29AM Seagen (SGEN) Reports PADCEV and KEYTRUDA Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 T
Sep 22, 2023 05:00AM
Sep 5, 2023 05:35AM
Sep 4, 2023 03:00PM
Sep 4, 2023 03:00PM
Aug 16, 2023 08:00AM
Aug 16, 2023 08:00AM
Aug 2, 2023 08:00AM Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
Jul 12, 2023 08:00AM
Jun 20, 2023 08:30AM
Jun 20, 2023 08:30AM
Jun 15, 2023 05:59AM
Jun 14, 2023 08:31PM
Jun 13, 2023 04:45AM
Jun 13, 2023 03:01AM Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin
May 2, 2023 08:00AM
Apr 27, 2023 08:00AM
Apr 3, 2023 05:01PM
Apr 3, 2023 05:00PM
Apr 3, 2023 05:00PM
Mar 13, 2023 06:45AM
Mar 13, 2023 06:45AM Pfizer Invests $43 Billion to Battle Cancer
Mar 13, 2023 06:45AM
Mar 9, 2023 06:30PM
Mar 9, 2023 06:30PM
Feb 15, 2023 04:02PM
Jan 19, 2023 02:22PM
Jan 19, 2023 02:21PM
Dec 20, 2022 06:47AM Merck (MRK), Seagen (SGEN) and Astellas Announce FDA Acceptance of sBLA for PADCEV with KEYTRUDA
Dec 20, 2022 06:45AM
Dec 20, 2022 06:45AM
Nov 10, 2022 01:14PM
Nov 10, 2022 01:12PM
Nov 10, 2022 07:05AM
Nov 10, 2022 07:05AM
Oct 27, 2022 04:02PM Seagen Reports Third Quarter 2022 Financial Results
Sep 27, 2022 08:03AM

251,368 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All